Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus EXEM FOAM KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus EXEM FOAM KIT.
ARAZLO vs EXEM FOAM KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
The active ingredient in EXEM FOAM KIT is diclofenac, a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to anti-inflammatory, analgesic, and antipyretic effects.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Apply to affected area twice daily. Exemestane is an aromatase inhibitor; this is a topical formulation.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life is approximately 5–6 hours in patients with normal renal function; prolonged in hepatic impairment.
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Primarily fecal via biliary elimination (>90% as unchanged drug and metabolites); renal excretion accounts for <10%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid